17 results
8-K
EX-10.2
LNTH
Lantheus Holdings Inc
14 Nov 22
Entry into a Material Definitive Agreement
7:29am
Approvals, including through managing the Post-Marketing Commitment and pharmacovigilance and through life cycle management, (v) any other activities
8-K
EX-10.1
LNTH
Lantheus Holdings Inc
14 Nov 22
Entry into a Material Definitive Agreement
7:29am
and pharmacovigilance and through life cycle management, (v) any other activities expressly required to be performed by LANTHEUS under the Manufacturing
8-K
EX-99.1
LNTH
Lantheus Holdings Inc
17 May 22
Regulation FD Disclosure
8:41am
to post-marketing life cycle management. Dr. Provost joined Lantheus from his firm, Theranostics Consulting, where he provides research and development
425
gcthdmln4
12 May 20
Business combination disclosure
4:31pm
424B3
z1bpoldvdjc8b fmwxyf
19 Mar 20
Prospectus supplement
9:02am
S-4/A
lr9hlf7aewx1c4 jeis
16 Mar 20
Registration of securities issued in business combination transactions (amended)
8:47am
425
49u5 plqr
8 Jan 20
Business combination disclosure
5:19pm
425
erwoaksj
13 Nov 19
Business combination disclosure
12:00am
S-4
yzv kd8irz4c
12 Nov 19
Registration of securities issued in business combination transactions
8:02am
425
8gyznya
4 Oct 19
Business combination disclosure
5:07pm
425
v70qdjfshsf4xi7 vswt
2 Oct 19
Business combination disclosure
5:17pm
8-K
EX-99.2
9u4h7rezymbrvlk
2 Oct 19
Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company
7:29am
425
EX-99.2
v2i644awc
2 Oct 19
Business combination disclosure
7:27am
10-K
o1y2a9cnoymw2fpfs
2 Mar 16
Annual report
12:00am
- Prev
- 1
- Next